Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma

Niu, Zhaojian; Wang, Wenhong; Niu, Xiao-Jun

doi:10.3748/wjg.v28.i46.6433

Cited by 16 publications

(6 citation statements)

References 496 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…203 Niu et al reviewed the molecular mechanisms of HCC recurrence by systemically introducing the tumor and TME-derived biomarkers associated with recurrence. 204 In comparison with these two review articles, our review emphasized the perturbations of TME after surgery and discussed what alternations occur after surgery and how the changes in TME may give rise to the onset and progression of HCC recurrence. The TME changes that are significantly correlated with recurrence were highlighted as potential therapeutic targets.…”

Section: Discussionmentioning

confidence: 99%

“…Yang et al discussed the potential mechanisms of HCC recurrence with an emphasis on tumor intrinsic factors such as EMT and autophagy 203 . Niu et al reviewed the molecular mechanisms of HCC recurrence by systemically introducing the tumor and TME‐derived biomarkers associated with recurrence 204 . In comparison with these two review articles, our review emphasized the perturbations of TME after surgery and discussed what alternations occur after surgery and how the changes in TME may give rise to the onset and progression of HCC recurrence.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma

Wang

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Surgery remains to be the mainstay of treatment for hepatocellular carcinoma (HCC). Nonetheless, its therapeutic efficacy is significantly impaired by postoperative recurrence, which occurs in more than half of cases as a result of intrahepatic metastasis or de novo tumorigenesis. For decades, most therapeutic strategies on inhibiting postoperative HCC recurrence have been focused on the residual tumor cells but satisfying therapeutic outcomes are barely observed in the clinic. In recent years, a better understanding of tumor biology allows us to shift our focus from tumor cells toward the postoperative tumor microenvironment (TME), which is gradually identified to play a pivotal role in tumor recurrence. In this review, we describe various surgical stress and surgical perturbation on postoperative TME. Besides, we discuss how such alternations in TME give rise to postoperative recurrence of HCC. Based on its clinical significance, we additionally highlight the potential of the postoperative TME as a target for postoperative adjuvant therapeutics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma

Wang

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…The molecular mechanisms of metastasis in HCC are complex and involve multiple processes such as epithelial–mesenchymal transition (EMT), by which epithelial cells lose their polarity and acquire a mesenchymal phenotype, allowing them to migrate and invade the surrounding tissues, angiogenesis [ 109 ], cell adhesion, proteases and immune evasion [ 110 ]. A recent study provided evidence that a five-gene signature related to EMT ( P3H1 , SPP1 , MMP1 , LGALS1 and ITGB5) could be a useful prognostic tool for HCC patients.…”

Section: Preclinical Evidence About Metformin Influence On Hcc Hallmarksmentioning

confidence: 99%

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?

Papadakos

Ferraro

Carbone

et al. 2023

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. There has been significant progress in understanding the risk factors and epidemiology of HCC during the last few decades, resulting in efficient preventative, diagnostic and treatment strategies. Type 2 diabetes mellitus (T2DM) has been demonstrated to be a major risk factor for developing HCC. Metformin is a widely used hypoglycemic agent for patients with T2DM and has been shown to play a potentially beneficial role in improving the survival of patients with HCC. Experimental and clinical studies evaluating the outcomes of metformin as an antineoplastic drug in the setting of HCC were reviewed. Pre-clinical evidence suggests that metformin may enhance the antitumor effects of immune checkpoint inhibitors (ICIs) and reverse the effector T cells’ exhaustion. However, there is still limited clinical evidence regarding the efficacy of metformin in combination with ICIs for the treatment of HCC. We appraised and analyzed in vitro and animal studies that aimed to elucidate the mechanisms of action of metformin, as well as clinical studies that assessed its impact on the survival of HCC patients.

show abstract

“…This is mainly due to the high possibility of intrahepatic metastasis and postoperative recurrence. 4 Therefore, elucidating the mechanism of HCC metastasis and recurrence is of great significance.…”

Section: Introductionmentioning

confidence: 99%

IL-6 Released from Hepatic Stellate Cells Promotes Glycolysis and Migration of HCC Through the JAK1/vWF/TGFB1 Axis

Zhu,

Gu,

et al. 2024

JHC

View full text Add to dashboard Cite

Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma

Cited by 16 publications

References 496 publications

The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma

The tumor microenvironment in the postsurgical liver: Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?

IL-6 Released from Hepatic Stellate Cells Promotes Glycolysis and Migration of HCC Through the JAK1/vWF/TGFB1 Axis

Contact Info

Product

Resources

About